Han-Soo Kim

Seoul National University Hospital
Country flagSouth Korea

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (9)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Background Osteosarcoma is the most common secondary malignancy among survivors of retinoblastoma. Most previous reports on secondary malignancy of retinoblastoma included all types of secondary malignancies without a focus on osteosarcoma, owing to its rarity. In addition, there are few studies suggesting tools for regular surveillance for early detection. Questions/purposes (1) What are the radiologic and clinical characteristics of secondary osteosarcoma after retinoblastoma? (2) What is the clinical survivorship? (3) Is a radionuclide bone scan a reasonable imaging modality for early detection in patients with retinoblastoma? Methods Between February 2000 and December 2019, we treated 540 patients for retinoblastoma. Twelve patients (six male, six female) subsequently developed an osteosarcoma in the extremities; two of these patients had two sites of osteosarcoma (10 femurs, four tibiae) . A Technetium-99m bone scan image was examined annually in all patients for regular surveillance after the treatment of retinoblastoma as per our hospital’s policy. All patients were treated with the same strategy as that used for primary conventional osteosarcoma, namely neoadjuvant chemotherapy, wide excision, and adjuvant chemotherapy. The median follow-up period was 12 years (range 8 to 21 years). The median age at the time of diagnosis of osteosarcoma was 9 years (range 5 to 15 years), and the median interval from retinoblastoma diagnosis to osteosarcoma diagnosis was 8 years (range 5 to 15 years). Radiologic characteristics were assessed with plain radiographs and MRI, while clinical characteristics were assessed through a retrospective review of medical records. For clinical survivorship, we evaluated overall survival, local recurrence-free survival, and metastasis-free survival. We reviewed the results of bone scans and clinical symptoms at the time of diagnosis for osteosarcoma after retinoblastoma. Results In nine of 14 patients, the tumor had a diaphyseal center, and five of the tumors were located at the metaphysis. The femur was the most common site (n = 10), followed by the tibia (n = 4). The median tumor size was 9 cm (range 5 to 13 cm). There was no local recurrence after surgical resection of the osteosarcoma, and the 5-year overall survival rate after the diagnosis of osteosarcoma was 86% (95% CI 68% to 100%). In all 14 tumors, the Technetium bone scan showed increased uptake in the lesions. Ten of 14 tumors were examined in clinic because of patient complaints of pain in the affected limb. Four patients showed no clinical symptoms detected by abnormal uptake on bone scan. Conclusion For unclear reasons, secondary osteosarcomas in patients who were alive after the treatment of retinoblastoma had a slight predilection for the diaphysis of the long bone compared with patients with spontaneous osteosarcoma in other reports. The clinical survivorship of osteosarcoma as a secondary malignancy after retinoblastoma may not be inferior to that of conventional osteosarcoma. Close follow-up with at least yearly clinical assessment and bone scans or other imaging modalities appears to be helpful in detecting secondary osteosarcoma after the treatment of patients with retinoblastoma. Larger multi-institutional studies will be needed to substantiate these observations.

Year:

2023

Collaborators (14)

Elisa Pala

Docenti di ruolo di IIa fascia

University of Padova

ITALY
View details

Hyun Jin Park

Pusan National University Children’s Hospital

SOUTH KOREA
View details

Gerhard M Hobusch

Ap Prof

Medical University of Vienna

AUSTRIA
View details

DAVIDE MARIA DONATI

Istituto Ortopedico Rizzoli

ITALY
View details

Thomas Baad-Hansen

VIP, Clinical Professor

Aarhus University

DENMARK
View details

Abdulrahman Alaseem

Associate Professor and Consultant

king saud university

SAUDI ARABIA
View details

Michael Mørk Petersen

Professor, DMSc

Rigshospitalet

DENMARK
View details

Min Wook Joo

The Catholic University of Korea

SOUTH KOREA
View details

Ryan Denu

Assistant Professor, Physician Scientist

University of Wisconsin-Madison

UNITED STATES
View details

ILKYU HAN

Professor

Seoul National University Hospital

SOUTH KOREA
View details

Minna Laitinen

University of Helsinki

FINLAND
View details

Hyoung Jin Kang

Professor

Seoul National University Hospital

SOUTH KOREA
View details

Kyung Taek Hong

Seoul National University College of Medicine

SOUTH KOREA
View details

Mohamed Omar

Professor

Hannover Medical School

GERMANY
View details